source
- Zongertinib Shows 76% Response Rate in HER2-Mutant NSCLC, Paving Way for Accelerated FDA ApprovalZongertinib achieved a 76% overall response rate and a median response duration of 15.2 months in treatment‑naïve patients with HER2‑mutant advanced or metastatic non‑small cell lung cancer. The da…
- Capivasertib plus fulvestrant shows numerical overall-survival gain in PIK3CA/AKT1/PTEN-altered advanced breast cancerThe CAPItello-291 phase III trial enrolled 708 patients with advanced breast cancer and randomized them 1:1 to receive capivasertib (400 mg twice daily on a 4‑on/3‑off schedule) plus fulvestrant, o…